OncoMatch/Clinical Trials/NCT06594640
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Is NCT06594640 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for diffuse large b-cell lymphoma.
Treatment: Mitoxantrone Hydrochloride Liposome · Rituximab (R) · Cyclophosphamide (CTX) · Vincristin · Prednisolone — This is a prospective clinical study to evaluate the safety and efficacy of R-CMOP in patients with newly diagnosed diffuse large B-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hematopoietic stem cell transplantation
History of hematopoietic stem cell transplantation
Cannot have received: anti-lymphoma treatment
Exception: excluding short-term or low-dose corticosteroids
Have received prior anti-lymphoma treatment, excluding short-term or low-dose corticosteroids
Cannot have received: NMPA-approved anticancer herbal medicines or proprietary Chinese medicines
Used any NMPA-approved anticancer herbal medicines or proprietary Chinese medicines within 14 days prior to the first dose
Lab requirements
Blood counts
Absolute value of neutrophils ≥ 1.5 × 10^9/L; Platelet ≥ 75 × 10^9/L; Hemoglobin≥80g/L. For patients with bone marrow involvement: ANC ≥ 1.0 × 10^9/L; Platelet count ≥ 50 × 10^9/L; Hemoglobin level ≥ 75 g/L.
Kidney function
Creatinine clearance ≥ 50 mL/min or serum creatinine ≤ 2× ULN
Liver function
AST, ALT ≤ 2.5 × ULN; AST and ALT ≤ 5 × ULN for patients with liver involvement. Total bilirubin ≤1.5 × ULN (≤ 3 × ULN for patients with Gilbert syndrome)
Cardiac function
No severe cardiac rhythm or conduction abnormalities, mean QTcF interval ≤ 450 ms, no acute coronary syndrome, congestive heart failure, stroke, or any other Grade 3 or higher cardiovascular event within 6 months, NYHA functional class < II, LVEF ≥ 50%, no factors increasing risk of QTc prolongation or arrhythmias, no uncontrolled hypertension
a.)Patients should meet the following requirements and must not have received treatment with cell growth factors or blood products within 14 days prior to the hematology test: Absolute value of neutrophils ≥ 1.5 × 10^9/L; Platelet ≥ 75 × 10^9/L; Hemoglobin≥80g/L. For patients with bone marrow involvement of lymphoma, the requirements are adjusted as follows: Absolute neutrophil count (ANC) ≥ 1.0 × 10^9/L; Platelet count ≥ 50 × 10^9/L; Hemoglobin level ≥ 75 g/L. b.)Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN; AST and ALT ≤ 5 × ULN for patients with liver involvement. Total bilirubin ≤1.5 × ULN (≤ 3 × ULN for patients with Gilbert syndrome); c.)Creatinine clearance ≥ 50 mL/min or serum creatinine ≤ 2× ULN; d.)Coagulation function: prothrombin time or activated partial thromboplastin time≤ 1.5 × ULN, and international normalized ratio ≤ 1.5;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify